TOT in combination with solifenacin or intravaginal prasterone in postmenopausal women with mixed urinary incontinence: A retrospective analysis in 112 patients.
mixed urinary incontinence
prasterone
sexual function
solifenacin
transobturator tape
Journal
Lower urinary tract symptoms
ISSN: 1757-5672
Titre abrégé: Low Urin Tract Symptoms
Pays: Australia
ID NLM: 101506777
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
revised:
18
01
2023
received:
02
09
2022
accepted:
12
02
2023
medline:
28
4
2023
pubmed:
5
3
2023
entrez:
4
3
2023
Statut:
ppublish
Résumé
The aim of this study was to compare the efficacy of the transobturator tape (TOT) procedure combined with solifenacin (TOT-S) or prasterone (TOT-P) in postmenopausal women affected by mixed urinary incontinence (MUI) with a predominant stress urinary incontinence component. This is a retrospective analysis including 112 patients: 60 patients of the TOT-S group and 52 patients of the TOT-P group. Physical examination, 3-day voiding diary, urodynamic tests, and Vaginal Health Index (VHI) were compared at the beginning of the analysis and after 12 weeks of follow-up (FU). Specific questionnaires were administered to indagate the impact on women's quality of life and sexual function. After 12 weeks of FU, the detrusor's peak flow pressure was significantly different between the two groups (p = .02). Detrusor overactivity decreased only in the TOT-P group (p = .05). At the end of FU, 58 patients (96.7%) of the TOT-S group and 50 patients (96.2%) of the TOT-P group were dry at the stress test. A significative group difference was observed in urge urinary incontinence (24 h) (p = .01) but not in the mean number of voids (24 h) and urgent micturition events (24 h). VHI improved only in the TOT-P group (12.57 ± 3.80 vs. 19.75 ± 4.13, p < .0001). The questionnaires and Patient Global Index of Improvement (PGI-I) scores showed comparable improvements, while the Female Sexual Function Index improved especially in the TOT-P group (p < .001). In postmenopausal women with MUI, TOT-P demonstrated the same effectiveness as TOT-S in reducing urinary symptoms. In addition, TOT-P increased VHI and sexual function scores compared with TOT-S.
Substances chimiques
Solifenacin Succinate
KKA5DLD701
Dehydroepiandrosterone
459AG36T1B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-101Informations de copyright
© 2023 John Wiley & Sons Australia, Ltd.
Références
Haylen BT, de Ridder D, Freeman RM, et al. An international Urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5-26.
Humburg J. Die Urininkontinenz der Frau: Einführung in die Diagnostik und Therapie [Female urinary incontinence: diagnosis and treatment]. Ther Umsch. 2019;73(9):535-540. doi:10.1024/0040-5930/a001038
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336.
Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017;3:17042. doi:10.1038/nrdp.2017.42 Erratum in: Nat Rev Dis Primers 2017 Nov 16;3:17097.
Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10:CD001405. doi:10.1002/14651858.CD001405.pub3
Matarazzo MG, Sarpietro G, Fiorito D, et al. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2021 Aug;263:67-71. doi:10.1016/j.ejogrb.2021.06.009
Collà Ruvolo C, Gabrielli O, Formisano C, et al. Prasterone in the treatment of mild to moderate urge incontinence: an observational study. Menopause. 2022;29(8):957-962. doi:10.1097/GME.0000000000002007
Shumaker S, Wyman JP, Uebersax JS, et al. Health related quality of life measures for women with urinary incontinence: the incontinence impact questionnaire and the urogenital distress inventory. Qual Life Res. 1994;3:291-306.
Klovning A, Avery K, Sandvik H, Hunskaar S. Comparison of two questionnaires for assessing the severity of urinary incontinence: the ICIQ-UI SF versus the incontinence severity index. Neurourol Urodyn. 2009;28(5):411-415.
Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1997;104:1374-1379.
Srikrishna S, Robinson D, Cardozo L. Validation of the patient global impression of improvement (PGI-I) for urogenital prolapse. Int Urogynecol J. 2010;21(5):523-528.
Bachman G. Urogenital ageing: an old problem newly recognized. Maturitas. 1995;Suppl. 1:S1-S5.
Crisp CC, Fellner AN, Pauls RN. Validation of the female sexual function index (FSFI) for web-based administration. Int Urogynecol J. 2015;26(2):219-222.
Haylen BT, Freeman RM, Swift SE, et al. An international Urogynecological Association (IUGA)/International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic floor surgery. Neurourol Urodyn. 2011;30(1):2-12.
de Leval J, Waltregny D. New surgical technique for treatment of stress urinary incontinence TVT-obturator: new developments and results. Surg Technol Int. 2005;14:212-221.
Blaivas JG, Groutz A. Bladder outlet obstruction nomogram for women with lower urinary tract symptomatology. Neurourol Urodyn. 2000;19(5):553-564.
Sahin MO, Sen V, Irer B, Yildiz G. The effects of menopause on the quality of life and long-term outcomes of transobturator tape treatment in women with stres urinary incontinence. Int Braz J Urol. 2020;46(5):716-724. doi:10.1590/S1677-5538.IBJU.2019.0331
Cardozo L, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18:47-53.
European Medicines Agency. Intrarosa: summary of product characteristics. 2019. http://www.ema.europa.eu/ Accessed 20 June 2019.
Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. 2019;26(2):220-224.
Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colón R. Solifenacin succinate for the treatment of symptoms of overactive bladder. Clin Ther. 2006;28(9):1247-1272. doi:10.1016/j.clinthera.2006.09.017
Hay-Smith EJ, Bø Berghmans LC, Hendriks HJ, de Bie RA, van Waalwijk van Doorn ES. Pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev. 2001;(1):CD001407. doi:10.1002/14651858.cd001407
Ford AA, Rogerson L, Cody JD, Aluko P, Ogah JA. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2017;7(7):CD006375. doi:10.1002/14651858.CD006375.pub4
Carletti V, Yacoub V, Grilli D, et al. Sequential combined approach in patients with mixed urinary incontinence: surgery followed by posterior tibial nerve stimulation. Minerva Obstet Gynecol. 2022. doi:10.23736/S2724-606X.22.05106-5 Epub ahead of print.
Pergialiotis V, Mudiaga Z, Perrea DN, Doumouchtsis SK. De novo overactive bladder following midurethral sling procedures: a systematic review of the literature and meta-analysis. Int Urogynecol J. 2017;28(11):1631-1638. doi:10.1007/s00192-017-3417-1
Schiavi MC, Faiano P, D'Oria O, Zullo MA, Muzii L, Benedetti PP. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: a retrospective analysis. J Obstet Gynaecol Res. 2018;44(3):524-531. doi:10.1111/jog.13541
Brady PH, Gin GT, Rosenblum E, Wilkinson LD. Female pelvic conditions: genitourinary syndrome of menopause. FP Essent. 2022;515:32-42.
Schiavi MC, D'Oria O, Aleksa N, et al. Usefulness of ospemifene in the treatment of urgency in menopausal patients affected by mixed urinary incontinence underwent mid-urethral slings surgery. Gynecol Endocrinol. 2019;35(2):155-159. doi:10.1080/09513590.2018.1500534
Schiavi MC, Sciuga V, Giannini A, et al. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? Gynecol Endocrinol. 2018;34(8):666-669. doi:10.1080/09513590.2018.1441398
Adamakis I, Katafigiotis I, Tyritzis SI, et al. Treating anterior vaginal wall prolapse with polypropylene mesh via the transoburator route minimizing the complications with the use of preventing measures. A prospective study with 2-year follow-up. Minerva Ginecol. 2015;67(3):231-238.